CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Outcomes and Effect of Treatment According to Etiology in HFrEF An Analysis of PARADIGM-HF Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure

Clinical Trial15 Nov 2021

JOURNAL:Circulation. Article Link

Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

J Butler, G Filippatos, TJ Siddiqi et al. Keywords: HFpEF; empagliflozin; health status

Full Text PDF